Nontuberculous Mycobacterial Infection Market Insights: In-Depth Look at Growth Trends, Market Size, and Opportunities for 2025-2034
2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!
Which Major Market Drivers Are Expected to Boost the Growth Potential of the Nontuberculous Mycobacterial Infection Market?
The upward trajectory of chronic obstructive pulmonary disease (COPD) prevalence is predicted to accelerate the expansion of the nontuberculous mycobacterial infection market in the future. Characterized by a continual and often progressive limitation of lung airflow, COPD is a chronic respiratory ailment. Patients with COPD suffering from Nontuberculous mycobacterial (NTM) infections usually face a higher reduction in forced expiratory volume in one second (FEV1) and a heightened rate of exacerbation. Vulnerability to NTM bacterial lung infections rises due to the weakening of the immune system and lung tissue damage caused by COPD. For instance, COPD rates reportedly commenced an upward trend between 2021 and 2022 according to a March 2023 report published by The Scottish Public Health Observatory (ScotPHO), a Scotland-based public health entity; male rates escalated from 83.2 to 97.6 per 100,000 persons and female rates from 72.6 to 97.3. Hence, the escalating prevalence of chronic obstructive pulmonary disease (COPD) fosters the expansion of the nontuberculous mycobacterial infection market. The anticipated surge of the nontuberculous mycobacterial infection market in the future is largely credited to the escalating prevalence of infectious diseases. Illnesses instigated by pathogenic microorganisms such as bacteria, viruses, fungi or parasites which can spread from one person to another are classified as infectious diseases, and they can lead to a range of symptoms and health issues. A rise in the prevalence of infectious diseases, including those that could result in Nontuberculous Mycobacterial (NTM) infections, has the potential to stimulate the NTM infection market’s expansion. This is achieved by heightening the awareness of these infections, resulting in more routine diagnostic tests and early detection, ramping up research and development efforts for NTM treatments, and elevated demand for therapies designed to target NTM pathogens due to increased healthcare focus on infectious diseases. The United Nations International Children’s Emergency Fund (UNICEF), a US-based intergovernmental organization of United Nations agencies, reported in November 2024 that pneumonia, a leading infectious disease, was responsible for the death of over 700,000 children annually, averaging approximately 2,000 children every day. Consequently, the surging prevalence of infectious diseases is fueling the expansion of the nontuberculous mycobacterial infection market.
Get Your Free Sample Report Now – Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13020&type=smp
#What Long-Term Growth Rate is Expected for theNontuberculous Mycobacterial Infection Market Between 2025 and 2034?
The market size for nontuberculous mycobacterial infections has seen substantial growth in the past few years. The market is expected to increase from $14.25 billion in 2024 to $15.11 billion in 2025, with a compound annual growth rate (CAGR) of 6.0%. The growth experienced in the previous period can be credited to advancements in diagnostic techniques, an increasing elderly population, awareness about cystic fibrosis and the availability of immunosuppressive drugs.
The market for nontuberculous mycobacterial infection is projected to experience robust growth in the upcoming years, with an estimated value of $19.57 billion by 2029, expanding at a CAGR of 6.7%. The substantial growth during this period can be linked to improvements in antimicrobial drug production, heightened awareness of NTM, advancements in genetic studies, and the application of telehealth and remote monitoring. The forecast period will likely show trends like tailored treatment methods, increased regulatory attention, combined therapies, and digital health resources.
You can Directly Purchase the Report Here:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13020
What Are the Key Market Innovations in theNontuberculous Mycobacterial Infection Market Over the Coming Years?
Prominent players in the nontuberculous mycobacterial infection market are adopting new strategies like fast track designation for drug approval to maintain their market standing. The Fast Track system is a procedure established by the FDA to speed up the development and examination of treatments for serious diseases with unfulfilled medical needs. For example, in July 2022, NUZYRA was granted a Fast Track Designation by the Food and Drug Administration, a federal agency based in the United States, for dealing with NTM lung disease caused by Mycobacterium avium complex (MAC). NUZYRA (omadacycline), an innovative broad-spectrum antibiotic, is carefully engineered to combat severe bacterial infections, which include those induced by resistant strains. This designation accelerates the development and review of the NUZYRA antibiotic, providing solutions for pressing unmet medical needs.
Who Are the Top Companies Driving Innovation and Growth in theNontuberculous Mycobacterial Infection Market?
Major companies operating in the nontuberculous mycobacterial infection market are Pfizer Inc., Johnson & Johnson, F. Hoffman La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol Myers Squibb, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceutical Company, Eli Lilly and Company, C.H. Boehringer Sohn AG & Co. KG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Astellas Pharma Inc., Vertex Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Horizon Therapeutics PLC, Lupin Limited, BioMarin Pharmaceutical Inc., Ionis Pharmaceuticals Inc., Insmed Incorporated, Paratek Pharmaceuticals Inc., Spero Therapeutics Inc., Aradigm Corporation, Dauntless Pharmaceuticals Inc., Validus Pharmaceuticals LLC.
Order Your Report Now For A Swift Delivery:
Which Key Market Segments Comprise the Nontuberculous Mycobacterial Infection Market and Drive Its Revenue Growth?
The nontuberculous mycobacterial infection market covered in this report is segmented –
1) By Drug Class: Macrolides, Rifampin, Aminoglycoside, Other Drug Classes
2) By Route Of Administration: Oral, Parenteral, Other Routes
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Macrolides: Azithromycin, Clarithromycin
2) By Rifampin: Rifampin, Rifabutin
3) By Aminoglycoside: Amikacin, Streptomycin
4) By Other Drug Classes: Ethambutol, Clofazimine, Linezolid
Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=13020&type=smp
Which Regions Are Emerging as Leaders in the Nontuberculous Mycobacterial Infection Market?
North America was the largest region in the nontuberculous mycobacterial infection market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in nontuberculous mycobacterial infection market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Browse Through More Reports Similar to the Global Nontuberculous Mycobacterial Infection Market 2025, By The Business Research Company:
Cough And Cold Preparations Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/cough-and-cold-preparations-global-market-report
Respiratory Disposables Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/respiratory-disposables-global-market-report
Respiratory Monitoring Devices Global Market Report 2024
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
